Chinese Expert Consensus for the Application of rh‑aFGF for Chronic Refractory Wounds（2026）PubMed

文献信息 Journal：Pharmaceuticals (Basel)，2026‑02‑17；19 (2):328 DOI：10.3390/ph19020328 PMID：41754868 制定机构：Chinese Medical Doctor Association (CMDA) 中国医师协会 ⚠️仅供学术资料阅读，不能替代临床诊疗，rh‑aFGF 为处方药物，需临床医师评估后使用。

Abstract（官方摘要）PubMed

Background and Objective Chronic refractory wounds not only persist and delay healing, causing physical and mental suffering to patients and reducing their quality of life, but also impose a heavy burden on their families and society. Recombinant human acidic fibroblast growth factor (rh‑aFGF), approved in China for decades, is a growth factor with multiple biological effects which can promote the healing of various wounds. It is crucial to develop an rh‑aFGF expert consensus for standardizing the clinical application of aFGF and enhancing its clinical value.

Methods The literature related to rh‑aFGF, including clinical trials, experimental research, and reviews, was collected and selected from PubMed, Web of Science, Medline, CNKI, and Wangfang databases. Expert recommendations were formulated by integrating clinical evidence quality, Delphi questionnaire survey, and multi‑expert panel consensus meetings.

Results A total of 12 consensus recommendations for clinical application of rh‑aFGF on chronic refractory wounds (CRWs) were developed: 7 strong recommendations, 4 moderate recommendations, 1 weak recommendation, covering multiple clinical scenarios. Recommendations specify treatment duration, dosage, wound indications, combined dressings and concomitant therapies.

Conclusions rh‑aFGF possesses important clinical value in chronic refractory wound repair. This consensus offers clinical references for rh‑aFGF management and may guide the application of other growth‑factor‑based therapeutics.

Keywords: recombinant human acidic fibroblast growth factor (rh‑aFGF); chronic refractory wounds; wound healing; expert consensus

Core Consensus Recommendations（共识核心 12 条要点英文精简版）

1. Pre‑treatment wound preparation（强推荐 Strong） Complete debridement of necrotic tissue, adequate infection control, optimization of underlying diseases (diabetes, peripheral vascular disease, hypoproteinemia) before rh‑aFGF topical application. rh‑aFGF should not be applied on heavily necrotic, purulent wounds without debridement.
2. Diabetic foot ulcers（强推荐 Strong） rh‑aFGF is recommended for non‑ischemic or moderately ischemic diabetic foot ulcers (Wagner 2‑3). Administer after thorough debridement; combine with glycemic control, off‑loading and vascular intervention when necessary.
3. Pressure injuries /pressure ulcers（强推荐 Strong） rh‑aFGF is suitable for stage 2‑4 pressure injuries after debridement. Must combine with pressure‑reduction nursing.
4. Venous leg ulcers（中等推荐 Moderate） rh‑aFGF may be used for venous leg ulcers after debridement, combined with compression therapy as fundamental treatment.
5. Traumatic/post‑surgical refractory wounds（强推荐 Strong） rh‑aFGF is recommended for traumatic and postoperative non‑healing wounds with adequate blood perfusion and residual granulation potential.
6. Radiation‑induced skin wounds（弱推荐 Weak） rh‑aFGF can be considered for radiation‑related chronic wounds when local infection is controlled; evidence is limited.
7. Malignant wounds（不推荐 Not recommended） rh‑aFGF is contraindicated for wounds with confirmed malignant tumor infiltration.
8. Dosage & administration（强推荐 Strong） Topical rh‑aFGF solution/spray applied evenly onto wound granulation surface, 1‑2 times daily. Ensure full contact between drug and wound bed. Avoid drug inactivation by high temperature, strong disinfectant residue.
9. Treatment course（强推荐 Strong） General treatment course: 4‑8 weeks. Evaluate wound response every 2 weeks; stop application if no obvious granulation improvement after 4 weeks.
10. Combination with wound dressings（强推荐 Strong） Compatible with sterile gauze, foam dressings, hydrocolloid; apply drug first then cover dressing. Avoid strong‑oxidant disinfectants directly mixing with rh‑aFGF.
11. Combination with negative‑pressure wound therapy NPWT（中等推荐 Moderate） rh‑aFGF can be used in conjunction with NPWT; drug delivery should avoid high‑pressure direct flushing which may inactivate growth factor.
12. Safety & surveillance（强推荐 Strong） Adverse events are rare, mainly local mild irritation. Long‑term repeated application needs clinical follow‑up. Stop medication when local allergy occurs. Tumor‑related safety surveillance is suggested for long‑term use.

Practical Clinical Notes

1. rh‑aFGF cannot replace etiological treatment: glycemic control, revascularization, infection control, debridement remain primary therapy for chronic wounds.
2. Growth factor is adjuvant reparative therapy, not suitable for malignant‑infiltrated wounds.
3. Avoid residual iodine‑containing disinfectants on wound bed before medication, to prevent protein denaturation and drug inactivation.

Access to original full‑text

‑ PubMed：https://pubmed.ncbi.nlm.nih.gov/41754868/PubMed ‑ MDPI Pharmaceuticals official website open‑access full‑text.